PDCD1 and non-small cell lung carcinoma: However, since Forde et al. [35] reported positive data on the safety, tolerability, and major pathologic response (MPR) of PD-1 blockade therapy in the neoadjuvant setting of patients with resectable NSCLC, immunotherapy has rapidly transformed the landscape of neoadjuvant management for resectable NSCLC patients.